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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of sentinel lymph node biopsy (SLNB) for the detection of nodal metastases (in the investigated
nodal basin) for the staging of cutaneous squamous cell cancer (cSCC).
To determine the diagnostic accuracy of imaging tests, including ultrasound, computed tomography, magnetic resonance imaging and
positron emission tomography, alone or in combination, for the detection of any metastasis for the staging of cutaneous squamous cell
cancer.
To determine the diagnostic accuracy of imaging tests for the detection of nodal metastases in the staging of cutaneous squamous cell
cancer.
To determine the diagnostic accuracy of imaging tests for the detection of distant metastases in the staging of cutaneous squamous cell
cancer.
We will estimate these separately for those undergoing primary staging and those who have experienced a disease recurrence.
Sources of heterogeneity
We will consider a range of potential sources of heterogeneity for investigation in each individual test review. These may vary between
reviews but may include the following.
i. Population characteristics
• Primary tumour site (head and neck, trunk, limb, and other)
• Primary staging versus mixed or unclear populations (i.e. including staging of recurrent disease)
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ii. Index test characteristics
• Differences in test positivity thresholds
iii. Reference standard characteristics
• Reference standard used (histology, clinical or imaging-based follow-up)
iv. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted blinded to the result of any other index test
• Presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
We anticipate that the volume of evidence retrieved will be small and will restrict our ability to formally investigate these sources of
heterogeneity; however, data permitting, we will examine any impact on the effectiveness of each index test for the primary target
condition and make recommendations for where further research might be required.
B A C K G R O U N D
Cochrane Skin (Nottingham) in collaboration with the Test Eval-
uation Research Group in the Institute for Applied Health Re-
search (TERG, Birmingham) are undertaking a series of Cochrane
Diagnostic Test Accuracy (DTA) reviews on the diagnosis and
staging of melanoma and keratinocyte skin cancers (basal cell and
cutaneous squamous cell carcinoma) as part of the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the current content and structure
of the programme.
As several reviews for each topic area will follow similar method-
ology, we have prepared generic protocols in order to avoid du-
plication of effort. This protocol concerns the evaluation of tests
for the staging of cutaneous squamous cell carcinoma, including
sentinel lymph node biopsy for detection of nodal metastases and
imaging tests for the detection of any metastatic disease. A sep-
arate Cochrane protocol is available for the staging of cutaneous
melanoma (Dinnes 2016) and for the diagnosis of melanoma
(Dinnes 2015a) and of keratinocyte skin cancers (Dinnes 2015b).
The Background and Methods sections of this protocol use some
text that was originally published in the protocol for the evalua-
tion of tests for the diagnosis of keratinocyte skin cancers (Dinnes
2015b) and the protocol for staging of melanoma skin cancer
(Dinnes 2016).
Table 1 provides a glossary of terms used.
Target condition being diagnosed
Skin cancer is the most common form of human cancer (WHO
2017). Although melanoma skin cancer is the most dangerous
form, most skin cancers, i.e. basal cell carcinoma (BCC) and cu-
taneous squamous cell carcinoma (cSCC), arise from keratinocyte
skin cells and are collectively called keratinocyte skin cancers. BCC
can arise from multiple stem cell populations, including from the
follicular bulge and interfollicular epidermis (Grachtchouk 2011),
and almost always remains localised. Primary cSCC arises from the
keratinising cells of the epidermis or its appendages. It is locally in-
vasive with the potential to metastasise and spread to local lymph
nodes and distant parts of the body. The term ’non-melanoma skin
cancers’ has been applied in the past to loosely denote BCCs and
cSCCs. We have instead opted to use the term ‘keratinocyte’, as to
use a term to denote the commonest human cancer as something
which it is not (i.e. ’non-melanoma’) is unusual, and furthermore
‘non-melanoma skin cancer’ can also include other forms of skin
cancer such as cutaneous T cell lymphoma and other adnexal skin
cancers.
2Tests to assist in the staging of cutaneous squamous cell carcinoma: a generic protocol (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The overall worldwide incidence of skin cancer is difficult to es-
timate, as there is often no requirement for BCC or cSCC to
be reported within most cancer registries (Lomas 2012). How-
ever, in 2003 the World Health Organization (WHO) estimated
that between 2 and 3 million skin cancers occur globally each
year (WHO 2003). BCC is estimated to account for around 80%
(Madan 2010) and cSCC around 16% (Gordon 2013) to 20%
(Rogers 2015) of skin cancer cases worldwide. A systematic review
of incidence studies found the highest reported estimate of cSCC
in Europe in Switzerland, at 28.9/100,000 person-years (1997
data), with rates generally lower in Northern European countries
(Lomas 2012). Incidence is higher in the USA and Australia, with
rates in men of 60/100,000 person-years reported in Alberta, 290/
100,000 in Arizona and 387/100,000 in Australia (an increase
from166 cases per 100,000 in 1985 (Australian Institute ofHealth
and Welfare 2016)). Based on data from 2000 to 2006, the an-
nual incidence rates of cSCC in England, Scotland and Northern
Ireland were 22.7 per 100,000, 27.0 per 100,000 and 30.6 per
100,000 person-years respectively (Lomas 2012).
The number of deaths each year attributed to cSCC in the USA
has been reported at between 3900 and 8800 (Karia 2013), com-
pared to 9710 for melanoma (American Cancer Society 2014).
Local recurrence and metastatic spread from cSCC at five years is
estimated at 8% and 5% respectively, with a five-year survival rate
following the development of metastatic spread of only 25% to
40% (Rowe 1992).
People with cSCC often present with an ulcer or firm (indurated)
papule, plaque, or nodule (Griffin 2016), often with an adher-
ent crust and poorly defined margins (Madan 2010). Some le-
sions do not give rise to any symptoms, whereas others can cause
itch, tenderness, pain or bleeding. Chronic ultraviolet light expo-
sure through recreation or occupation is strongly linked to cSCC
occurrence (Alam 2001) and it is therefore particularly common
in people with fair skin and in less common genetic disorders
of pigmentation such as albinism and xeroderma pigmentosum
(Alam 2001). cSCC can arise in the absence of a precursor lesion
or it can develop from pre-existing actinic keratosis with an esti-
mated annual risk of progression of less than 1% to 20% (Alam
2001). Bowens disease (squamous cell carcinoma in situ) is an-
other precursor lesion which can lead to cSCC (estimated annual
risk of progression 5% (Kao 1986)), especially if associated with
human papilloma virus (HPV) in genital sites. Other recognised
risk factors for cSCC development include immunosuppression,
chronic wounds such as long-standing venous ulcers, arsenic or
radiation exposure, certain drug treatments such as voriconazole
and BRAF inhibitors, and previous skin cancer history (Chowdri
1996; Baldursson 1993; Dabski 1986; Fasching 1989; Karagas
2015; Lister 1997; Maloney 1996; O’Gorman 2014). In trans-
plant recipients, cSCC is the most common form of skin cancer;
the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999).
A cSCC lesion remains locally invasive for a variable length of time,
but it has the potential for spread to the regional lymph nodes
or via the bloodstream to distant sites, especially in immunosup-
pressed individuals (Lansbury 2010). The histopathological fac-
tors established as of prognostic significance for cSCC are now part
of the Royal College of Pathologists minimum data set for report-
ing (Royal College of Pathologists 2014). Indicators of high-risk
status include diameter greater than 2 cm (Clayman 2005; Rowe
1992); microscopic depth greater than 4 mm or extending be-
yond dermis (Breuninger 1990; Clayman 2005; Friedman 1985;
Rowe 1992); poor differentiation (Rowe 1992); acantholytic, spin-
dle and desmoplastic subtypes; perineural or lymph vascular in-
volvement (Cottel 1982; Mendenhall 1989; Moore 2005). Addi-
tional factors potentially associated with poor prognosis include
immunosuppression (Barksdale 1997); lesions situated in chronic
wounds; Bowens disease; areas of radiation or thermal injury; non-
sun-exposed sites; ear or lip (Afzelius 1980; Motley 2009; Rowe
1992).
The American Joint Committee on Cancer’s TNM prognos-
tic classification system (currently AJCC-7) (American Joint
Committee on Cancer 2010) is based on tumour size, degree of
infiltration and presence of and extent of nodal metastasis and
distant metastasis (Table 2). Those with nodal involvement are
automatically assigned to stage III (and may be upstaged accord-
ing to the number and location of diseased nodes or the presence
of disseminated disease), while those with confirmed local disease
are assigned a stage between 0 and III, according to histological
tumour staging (tumour size and presence of high-risk features in-
cluding depth/invasion, anatomical location, and differentiation)
(American Joint Committee on Cancer 2010).
The AJCC-7 (American Joint Committee on Cancer 2010) classi-
fication system has been criticised for its development in head and
neck lesions, lack of clinical validation beyond organ transplant
recipients with cSCC and inability to distinguish sufficiently be-
tween low- andhigh-riskT2 tumours (Jambusaria-Pahlajani 2013;
Schmitt 2014; SIGN 2014; Stratigos 2015). In order to more pre-
cisely identify tumours with a high risk of metastasis and death,
Jambusaria-Pahlajani 2013 has developed an alternative T-staging
system based on analysis of a group of 256 people with primary
high-risk cSCCs. Those risk factors found to be strong indepen-
dent prognostic predictors of local recurrence, nodal metastasis,
disease-specific death, and all-cause death on multivariate analysis
included tumour diameter of 2 cm or more, poorly-differentiated
histological characteristics, perineural invasion, and tumour inva-
sion beyond the subcutaneous fat, with bone invasion automati-
cally upgrading the tumour to stage T3 (Table 3). When classified
according to the new system, local recurrence, nodal metastasis,
disease-specific death, and all-cause death occurred significantly
more often in stage T2b rather than T2a, whereas according to the
AJCC-7 classification system these outcomes occurred in Stage 2
with no further differentiation (Jambusaria-Pahlajani 2013). The
new approach may better identify those at high risk of disease pro-
gression or later recurrence.
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In terms of nodal disease, staging for cSCC primarily relies on
clinical examination with palpation of the regional lymph nodes
to identify any nodal involvement (Motley 2009; NCCN 2013;
Stratigos 2015), which increases the risk of recurrence and mor-
tality (survival rate of 30% at five years) (Stratigos 2015). Current
staging systems do not account for the presence of micrometastatic
disease as identified by sentinel lymph node biopsy (SLNB). How-
ever Schmitt 2014 has applied the AJCC-7 system and the alter-
native system proposed above to a cohort of 130 people taken
from the literature, to identify which was most closely associated
with positive SLNB findings (micrometastasis). Using the AJCC-
7 classification, positive SLNB results were found in T2 tumours
(in 13 of 116 patients (11.2%), but in none of those less than 2
cm in diameter) and T4 tumours (three of five; 60%); whereas for
the alternative system positive SLNB results were found in those
grouped as T2a (six of 85; 7.1%), T2b (five of 17; 29.4%) and
T3 (three of six; 50%) (Schmitt 2014).
Treatment of cSCC
The British Association of Dermatology multi-professional guide-
line (Motley 2009) strongly emphasises three important points
about treatment of SCC: the lack of randomised evaluation of
treatment for SCC; the variation in behaviour of SCC tumours;
and the varied experience of those treating cSCC, with dermatol-
ogists primarily dealing with lower-risk lesions, and higher-risk,
more aggressive tumours referred to plastic and maxillofacial sur-
geons. Furthermore, the guideline points to “the need for complete
removal or treatment of the primary tumour, the possible presence
of local ‘in transit’ metastases”, and “the tendency of metastases to
spread by lymphatics to lymph nodes”. A 2010 Cochrane Review
identified a single RCT in cSCC showing no evidence of bene-
fit from adjuvant 13-cis-retinoic acid and interferon alpha after
surgery (Lansbury 2010). Current practice therefore relies on ev-
idence from observational studies, as reviewed, for example, by
Lansbury 2013.
The standard treatment for SCC is usually surgical excision with
predetermined margins (Motley 2009; Stratigos 2015); however,
other locally destructive techniques can be employed as indicated,
especially for smaller lesions. These include freezing (cryotherapy)
or electrodessication and curettage; non-surgical treatments in-
cluding topical imiquimod; and photodynamic therapy (Motley
2009; Stratigos 2015). The European Dermatology Forum-Eu-
ropean Association of Dermato-Oncology-European Organiza-
tion ofResearch andTreatment ofCancer (EDF-EADO-EORTC)
consensus group have recommended standardised minimal sur-
gical margins according to the presence of risk factors including
vertical thickness, histological grade, subcutaneous invasion, per-
ineural invasion, and tumour site (Bonerandi 2011). Mohs mi-
crographic surgery, whereby horizontal sections of the tumour
undergo histological analysis and re-excisions are made until the
margins are tumour-free, can be considered where standard wider
excision margins might lead to considerable functional impair-
ment (Lansbury 2010;Motley 2009; Stratigos 2015). A systematic
review and meta-analysis of observational studies of treatments
for cSCC suggest low recurrence rates for small, low-risk lesions
treated with cryotherapy or curettage and electrodesiccation (re-
currence rates less than 2%) (Lansbury 2013). Results for Mohs
microsurgery, surgical excision, or radiotherapy which are likely
to have been evaluated in higher-risk populations, showed pooled
recurrence rates of 3%, 5.4% and 6.4% respectively, and with
overlapping confidence intervals; the review authors advise cau-
tion when comparing results across treatments (Lansbury 2013).
Photodynamic therapy is currently not recommended for use in
cSCC in the SIGN guideline, due to lack of evidence (SIGN
2014). Radiotherapy may also be an option for non-surgical treat-
ment of inoperable small cSCCs, with some evidence of good local
control (Fort 2016). Electrochemotherapy (where chemotherapy
is administered either intravenously or directly into the tumour,
followed by brief and intense electric pulses around or directly into
the tumour (NICE 2014)) may be used to control the progres-
sion of inoperable loco-regional SCC recurrences (Stratigos 2015);
however, evidence is scarce and based on mixed populations of
people with BCC and cSCC (NICE 2014).
Intralesional 5-Fluorouracil (5-FU) alone may also be considered
as a therapeutic option in invasive cSCC, although it is not com-
monly used in the UK and available evidence appears to be based
on treatment of keratoacanthoma rather than invasive SCC (Good
2011; Kirby 2010).
As most cSCC is localised, elective lymph node dissection is gen-
erally not undertaken (Motley 2009) and the role of SLNB is yet
to be established (Stratigos 2015). In the presence of clinically-
detectable nodal disease, regional lymph node dissection is under-
taken (Stratigos 2015). Guidelines also recommend that adjuvant
or post-operative radiotherapy can be considered where there is
substantial perineural involvement, when tissue margins are not
tumour-free after surgical excision, and in the presence of regional
disease (NCCN2013; SIGN 2014; Stratigos 2015). TheNational
Comprehensive Care Network (NCCN) guideline highlights two
small retrospective studies (Veness 2005; Givi 2011) suggesting
that adding radiotherapy to lymph node dissection improves dis-
ease-free survival (NCCN 2013). The evidence for systemic treat-
ment in an adjuvant setting or for treatment of metastatic disease
is scarce, with no available phase III trials (SIGN 2014). Chemo-
therapeutic agents that have been used include cisplatin or carbo-
platin, 5-fluorouracil, bleomycin, methotrexate, adriamycin, tax-
anes, gemcitabine or ifosfomide (NCCN 2013; Stratigos 2015).
Although the prognosis for people with localised cSCC is gen-
erally very good, accurate diagnosis and staging to allow timely
management may be important to reduce potentially significant
morbidity, particularly if potentially effective new drugs to treat
systemic disease become available.
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Index test(s)
With such limited evidence for systemic therapies, interest in the
staging of cSCC has largely focused on locoregional or nodal stag-
ing to determine whether lymph node dissection is required. The
first step in this process is the identification of high-risk patients
on histopathology and the initial clinical examination and detailed
history-taking, including palpation of the regional lymph nodes
followed up with fine-needle aspiration cytology or core biopsy
of enlarged lymph nodes. Lymph node ultrasound may also be
used (Motley 2009; NCCN 2013; Stratigos 2015). SLNB is a
technique that is increasingly used for nodal staging in a range of
cancers but its role in cSCC has yet to be established.
In terms of imaging tests other than ultrasound, the evidence for
computed tomography (CT), magnetic resonance imaging (MRI)
and positron emission tomography-computed tomography (PET-
CT) is unclear. The SIGN guideline suggests that evidence for
further imaging such as MRI has to be extrapolated from evidence
of its use in the management of other cancers such as squamous
cell cancer of the head and neck (SIGN 2014).
Ultrasound
Ultrasound can be used as an alternative or adjunct to palpation
for detection of enlarged lymph nodes, and is usually followed
by fine-needle aspiration cytology or core biopsy to confirm the
presence of metastases. It has been highly recommended in the
absence of clinically-enlarged nodes (Bonerandi 2011; Motley
2009), particularly for people with tumours that have high-risk
characteristics (Jank 2003).
We found no systematic reviews of ultrasound in cSCC from our
scoping searches.
Sentinel lymph node biopsy (SLNB)
For melanoma skin cancer, sentinel node biopsy is usually per-
formed by a plastic surgeon, following wide local excision of the
primary tumour (NICE 2015). A radioactive tracer and blue dye
are injected into the skin surrounding the primary lesion and the
’sentinel’ lymph nodes to which the tracer drains are located by
imaging (usually lymphoscintigraphy) and then removed and ex-
amined for nodal metastatic spread that cannot be detected clin-
ically or on imaging (NICE 2015). Although the SLNB result
directly informs pathological staging of melanoma (Balch 2009),
this is currently not the case for cSCC, and the prognostic and
therapeutic role for SLNB remains unclear. Given that regional
lymph node dissection would normally be undertaken in the pres-
ence of lymph node involvement, the accuracy of SLNB for de-
tection of lymph node metastases according to primary tumour
site is of clinical interest.
Previous systematic reviews of SLNB in cutaneous cSCC have
found some limited data to suggest few false-negative results and
lowmorbidity from the procedure (Ahmed 2014; Allen2015;Ross
2006), with further potentially eligible primary studies continuing
to emerge (Gore 2016).
SLNB is useful only for the detection of locoregional disease via
lymphatic spread, whereas the imaging-based tests discussed be-
low can also detect distant metastatic disease which occurs via
lymphatic or haematogenous spread. Imaging tests are undertaken
and interpreted by radiologists with decisions about patient man-
agement following imaging or SLNB made at multidisciplinary
team meetings (MDTs) as discussed in the Clinical pathway sec-
tion below.
Computed Tomography (CT; non-contrast or
contrast-enhanced)
CT scans use X-rays to take cross-sectional images of the
body, which can then be combined to create 3D images (
Oncolink 2016b). The procedure involves small amounts of
radiation according to the area of the body to be scanned (
www.radiologyinfo.org/en/info.cfm?pg=safety-xray), and can also
be conducted using an intravenous contrast agent (contrast-en-
hanced) to allow blood vessels or lymph nodes to be assessed.
We found no systematic reviews of CT use in cSCC from our
scoping searches.
Magnetic Resonance Imaging (MRI; non-contrast or
contrast-enhanced)
MRI scans use magnets and radiowaves rather than radiation to
generate images, which are then computer-processed to produce
cross-sectional ’slices’ of the body. MRI scans are more expensive
and take longer to carry out compared to CT scans (Oncolink
2016bc).
We found no systematic reviews of MRI for cSCC staging from
our scoping searches.
18FDG - Positron emission tomography (PET)
Positron emission tomography (PET) is a nuclear medicine tech-
nique whereby a radioactive glucose (usually 18FDG) is adminis-
tered intravenously, and is then metabolised as part of the body’s
normal function. The PET scanner detects the FDG and an image
is created using colours to show where the FDG has been taken
up; tumours take up more FDG than normal tissue, due to a
higher rate of metabolism, with malignant masses generally being
more ’active’ than benign ones (Oncolink 2016d). PET can also
be combined with CT to provide both functional and structural
information. The use of PET in combination with CT will neces-
sarily increase the radiation exposure of the patient (RPOP 2016).
We found no systematic reviews of PET for cSCC staging from
our scoping searches. One small case series suggests that PET-CT
may be useful for nodal staging in high-risk patients, e.g. those
with chronic lymphocytic leukaemia (Tomaszewski 2014), while
others suggest that management in most people with head-and-
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neck cSCC with regional metastasis does not change with the
addition of PET-CT (Supriya 2014).
Clinical pathway
The recommendations on the staging of cSCC following diagnosis
as described in the UK (Motley 2009; SIGN 2014), Europe (
Stratigos 2015), Australia (Cancer Council Australia 2008) and
the USA (NCCN 2013) are summarised in Figure 1 and outlined
below; however, it should be noted that practice may vary across
and between countries.
Figure 1. Summary of guideline recommendations for the staging of cutaneous ACC following primary
diagnosis
Although cSCC can be locally very invasive, it is primarily a lo-
calised disease; the early identification of high-risk tumours that
are most likely to recur locally or to have nodal involvement is key
to clinical management (Cancer Council Australia 2008; Motley
2009; SIGN 2014). In the UK National Health Service (NHS),
all people with suspected cSCC are referred via the two-week wait
referral pathway to an appropriately-trained specialist (London
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Cancer Alliance 2013). On histological confirmation of the pres-
ence of SCC and wide local excision of the primary lesion, pa-
tients undergo a full clinical examination of both the skin and
regional lymph nodes with fine-needle aspiration cytology or core
biopsy of enlarged lymph nodes (Motley 2009; NCCN 2013;
SIGN 2014; Stratigos 2015). The result of this examination and
the histopathology results are used for initial staging of the tu-
mour; those considered to be at high risk of metastatic spread
may then undergo further staging investigations as determined
by a multidisciplinary team (MDT). In the UK NHS, all people
identified as being at high risk are considered at an MDT meet-
ing (SIGN 2014). These teams may include dermatologists, sur-
geons (including plastic surgeons), oncologists, radiologists, spe-
cialist nurses, GPswith a special interest in skin cancer, physiother-
apists, psychologists, lymphoedema services, occupational thera-
pists, cosmetic camouflage advisers and histopathologists (NICE
2010).
High-risk SCCs as defined by the National Institute for Health
and Care Excellence (NICE) (and similarly in the SIGN 2014
guideline) are histologically “poorly differentiated, perineural in-
vasion, depth greater than 4 mmor extending to subcutaneous tis-
sue (Clark level 5)”, situated on “lip, ears, non-sun-exposed sites,
e.g. penis, scrotum and soles of feet; in areas of previous injury,
e.g. burns, irradiation and chronic ulcers” and with greater than
2 cm diameter, immunosuppression, or previously-treated lesion
(NICE 2010). Similar factors are considered in Australian guide-
lines with a recommendation for specialist referral for all cSCC
of the central face, scalp, lip and ear due to higher risk of local
recurrence and the possible need for specialist reconstruction tech-
niques (Cancer Council Australia 2008).
Staging investigations that may be initiated by the MDT include:
• SLNB (a technique that is increasingly used for nodal
staging in a range of cancers but whose role in cSCC has yet to
be established (SIGN 2014)); or
• imaging tests, such as ultrasound, CT, MRI, or PET-CT.
Ultrasound may be considered for nodal assessment in the absence
of clinically-enlarged nodes (Motley 2009;NCCN2013; Stratigos
2015), especially in higher-risk cases, such as SCC of the head and
neck, to look at the different levels of nodes to determine whether
lymph node dissection is feasible or not. In Australia , any clinical
suspicion of lymph node involvement warrants investigation by
CTor ultrasound,with diagnosis of nodalmetastases confirmedby
fine-needle aspiration cytology (Cancer Council Australia 2008).
The use of CT or MRI is generally based on clinical indication
(NCCN 2013; SIGN 2014; Stratigos 2015), for example if per-
ineural invasion is suspected (Cancer Council Australia 2008). In
the elderly and in transplant recipients, whole-body CT may be
used in case of more aggressive disease or to identify any internal
SCC. People with chronic lymphatic leukaemia (CLL) are another
high-risk group and a classic dilemma in SCC, as lymph nodes
may be enlarged due to the CLL but the associated immunosup-
pression increases the incidence and rate of recurrence of SCC
(Jennings 2010).
Follow-up after treatment relies on skin self-examination with
“close medical examination” (Motley 2009) of those with high-
risk lesions (SIGN 2014), with imaging to detectmetastatic spread
undertaken on development of recurrence (SLNB is used only on
primary presentation of skin cancer and is rarely employed for
staging of recurrence, even for melanoma (Beasley 2017)).
Role of index test(s)
The assessment of people with cSCC lesions relies heavily on clin-
ical examination, history and histological assessment; only a small
percentage of them experience any disease spread (Rowe 1992),
such that further disease staging is often not required. However,
there is a small proportion of people with subclinical or dissem-
inated disease in whom further investigations may be warranted
(Rowe 1992). For people withmelanoma, SLNBprovides ameans
of identifying those without clinically palpable lymph nodes who
may benefit from complete lymph node dissection, although the
overall benefit to patients in terms of disease-free or overall sur-
vival is as yet unclear (Sladden 2015). People with cSCC, however,
do not generally undergo lymph node dissection unless they have
clinically palpable lymph nodes (Motley 2009), as the prognos-
tic significance of subclinical or micrometastatic disease is even
less clear, primarily due to the small evidence base. There is some
evidence, however, that micrometastatic disease can be identified
in a significant proportion of those with high-risk tumours who
do not have clinically palpable lymph nodes (Gore 2016; Schmitt
2014).
Imaging tests are recommended at the discretion of the clinicians
concerned, and are used for both regional lymph nodes and to
identify any more distant disease. The current evidence base is
poor, indicating a need to further define any potential role of
ultrasound, CT, MRI and PET-CT.
Alternative test(s)
When clinically-palpable lymph nodes are identified, core-needle
biopsy or fine-needle aspiration cytology of the lymph node may
be undertaken to confirm the presence of macrometastases, i.e.
metastases that are visible to the naked eye (Marsden 2010). Fine-
needle aspiration is a fairly simple procedure which allows a sample
of cells to be taken from the lymph node with a fine needle (Hall
2013), while core-needle biopsy uses a slightly larger needle with
a hollow centre, allowing the removal of a core of tissue with
the cell structure intact (Oncolink 2016a). Both procedures can
be guided by simple palpation or, for more deep-seated lesions,
by image-based techniques such as ultrasound (Bohelay 2015).
Although the accuracy of core-needle biopsy in comparison tofine-
needle aspiration has been identified as a key clinical question to be
investigated by our advisory group, it is beyond the scope of these
reviews, which focus on the detection of nonpalpable metastatic
disease.
7Tests to assist in the staging of cutaneous squamous cell carcinoma: a generic protocol (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
As with melanoma, biomarkers have potential more as indicators
of prognosis in people with cSCC rather than as staging tools in
themselves. The SIGN guideline identified only a small number
of preliminary retrospective studies focusing on high-risk tumours
(SIGN 2014).
Rationale
Staging of cSCC relies predominantly on histopathological classi-
fication and clinical examination to identify nodal spread. Further
investigations will be considered only in those people identified as
having high-risk cSCC; however, the evidence to support the use
of additional investigations is relatively sparse.
Currently-available systematic reviews of SLNB in cSCC suffer
frombeing out of date, with searches covering periods up to 2006 (
Ross 2006) and 2012 (Allen 2015), or restriction to certain patient
groups, such as head and neck (Ahmed 2014). Although SLNB is
not routinely used for cSCC, there is a need to keep a watching
brief on the evidence in a developing field.
In terms of imaging, we found no systematic reviews in cSCC;
nevertheless, imaging is used in certain high-risk groups of patients
and therefore any evidence to support or refute its use needs to be
collected and systematically evaluated.
Our approach will allow any evidence for the accuracy of SLNB
and of imaging tests in staging cSCC to be estimated. This generic
protocol provides themethodology that we will use for our reviews
of tests to assist in the staging of cSCC. We will appropriately
tailor the Background sections for each individual test review.
O B J E C T I V E S
To determine the diagnostic accuracy of sentinel lymph node
biopsy (SLNB) for the detection of nodal metastases (in the in-
vestigated nodal basin) for the staging of cutaneous squamous cell
cancer (cSCC).
To determine the diagnostic accuracy of imaging tests, including
ultrasound, computed tomography, magnetic resonance imaging
and positron emission tomography, alone or in combination, for
the detection of any metastasis for the staging of cutaneous squa-
mous cell cancer.
Secondary objectives
To determine the diagnostic accuracy of imaging tests for the de-
tection of nodal metastases in the staging of cutaneous squamous
cell cancer.
To determine the diagnostic accuracy of imaging tests for the de-
tection of distant metastases in the staging of cutaneous squamous
cell cancer.
We will estimate these separately for those undergoing primary
staging and those who have experienced a disease recurrence.
Sources of heterogeneity
We will consider a range of potential sources of heterogeneity
for investigation in each individual test review. These may vary
between reviews but may include the following.
i. Population characteristics
• Primary tumour site (head and neck, trunk, limb, and
other)
• Primary staging versus mixed or unclear populations (i.e.
including staging of recurrent disease)
ii. Index test characteristics
• Differences in test positivity thresholds
iii. Reference standard characteristics
• Reference standard used (histology, clinical or imaging-
based follow-up)
iv. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted blinded to the result of any other
index test
• Presence of partial or differential verification bias (whereby
only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection
dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
We anticipate that the volume of evidence retrieved will be small
and will restrict our ability to formally investigate these sources
of heterogeneity; however, data permitting, we will examine any
impact on the effectiveness of each index test for the primary target
condition and make recommendations for where further research
might be required.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We will include test accuracy studies that allow comparison of
results of the index test with that of a reference standard, including
the following:
• prospective and retrospective studies;
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test(s) (concurrently) and a reference standard;
• studies where participants are allocated by any method to
receive different index tests or combinations of index tests and all
receive a reference standard (between-person comparative studies
(BPC));
• studies that recruit series of participants unselected by true
disease status; and
• diagnostic case-control studies that separately recruit
diseased and non-diseased groups (see Rutjes 2005).
We will exclude follow-up or surveillance studies using repeated
imaging tests to detect disease recurrence, as defining the most
appropriate follow-up schedule for cSCC is not an objective of
these reviews. Given the lack of reliability in the interpretation
of studies with very small sample sizes, we will apply a sample
size restriction of at least five disease-positive participants. As we
anticipate a paucity of evidence meeting this criterion, if we find
fewer than five studies meeting this criterion for any one test, we
will include studies with fewer than five cases.
We will include studies reporting either lesion-based or partici-
pant-based analyses, but only those reporting data on a per-patient
basis in the primary analysis.
Participants
We will include studies in adults with cSCC at any primary site
who are undergoing staging, either following primary presenta-
tion of disease or following recurrence of disease. We will include
studies of mixed populations of participants or where we cannot
determine the clinical pathway, and will examine any effect on test
accuracy in subgroup analysis. We will exclude studies in which
test results for participants with cSCC cannot be differentiated
from those of participants with other diagnoses.
For studies of SLNB, outcomes must be presented for both sen-
tinel lymph node-positive and sentinel lymph node-negative par-
ticipants. For studies of imaging tests, we will include studies fo-
cusing on either sentinel lymph node-positive or sentinel lymph
node-negative participants.
Index tests
We will undertake individual reviews for SLNB and for the fol-
lowing imaging tests, either alone or in combination:
• ultrasound (with or without subsequent fine-needle
aspiration cytology or core biopsy)
• CT (non-contrast or contrast-enhanced)
• PET or PET-CT (18FDG only)
• MRI (non-contrast or contrast-enhanced)
SLNB studies may assess the effectiveness of methods of detection
of SLNs, for example using different tracers or dyes or alternative
imaging approaches. Thesewill often compare approaches in terms
of the number of diseased nodes identified, and we will exclude
them unless an eligible reference standard, as described below, has
been used.
Target conditions
The target condition for the SLNB review will necessarily be de-
fined differently according to the result of the index test as follows:
• For SLN-positive participants, the presence of
micrometastasis in the nodal basin investigated by the SLNB
procedure
• For SLN-negative participants, the emergence of clinically-
detectable nodal disease or macrometastases in the nodal basin
investigated by the SLNB procedure in the absence of evidence
of distant metastases; the latter is in order to increase the
likelihood that a nodal recurrence in SLN-negative participants
is more likely to be a false negative if there is no disease elsewhere
in the body
• In the event of inadequate data, we will drop the
requirement to confirm the absence of distant metastases in
SLN-negative participants, and will consider the emergence of
any nodal disease in the nodal basin investigated by the SLNB
procedure a sufficient definition of a false negative result
The target conditions for the imaging test reviews are the detection
of:
• any metastases;
• any nodal metastases;
• any distant metastases.
The use of the same tests for the staging of cutaneous melanoma
is the subject of a separate protocol (Dinnes 2016).
Reference standards
Acceptable reference standards include:
• Histology of lymph node or distant specimens, with
samples obtained by core biopsy, SLNB or lymph node
dissection, for index test-positive participants
• Cytology of lymph node specimens, with samples obtained
by core biopsy, or fine-needle aspiration, for index test-positive
participants
• Clinical or radiological follow-up to identify nodal or
distant recurrence of at least three months, for index test-
negative participants
• Any combination of the above
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Studies using cross-sectional imaging-based reference standards
(i.e. a direct comparison of the index test versus an alternative
reference standard imaging test) will not be eligible.
Search methods for identification of studies
The Information Specialist (SB) will carry out a comprehensive
search for published and unpublished studies. As previously men-
tioned, a series of Cochrane Diagnostic Test Accuracy (DTA) re-
views on the diagnosis and staging of melanoma and keratinocyte
skin cancers is being carried out as part of a National Institute for
Health Research (NIHR) Programme Grant.
Electronic searches
We have conducted a single large literature search for the pro-
gramme grant, covering all conditions and tests. This allowed for
the screening of search results for potentially relevant papers for
all reviews at the same time. We formulated a MEDLINE scoping
search combining disease-related terms with terms related to the
test names, using both text words and subject headings. As most
records were related to the searches for tests for the staging of dis-
ease, we applied a filter using terms related to cancer staging and
to accuracy indices to the staging test search, to try to eliminate
irrelevant studies, e.g. those using imaging tests to assess treatment
effectiveness. We screened a sample of 300 records that would be
missed by applying this filter and adjusted the filter to make sure
that we would not miss any potentially relevant studies. The final
search filter (Appendix 2) reduces the overall numbers retrieved
from MEDLINE by around 6000. We cross-checked the final
search result against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study is not indexed on MEDLINE. The Information Specialist,
Susan Bayliss, has devised the search strategy, with input from the
Information Specialist from Cochrane Skin, Elizabeth Doney. We
used no additional limits.
We undertook further scoping searches to identify any relevant
systematic reviews or health technology assessments. In addi-
tion to general bibliographic databases, we also accessed specialist
databases with a focus on reviews of diagnostic test accuracy, such
as ARIF.
We have now searched the following bibliographic databases, re-
trieving a total of 33,994 unique records:
Published studies
The Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane Library; the Cochrane Database of Systematic
Reviews (CDSR) in the Cochrane Library; CRD Database of
Abstracts of Reviews of Effects (DARE); CRD HTA (Health
Technology Assessment) database; MEDLINE via OVID (from
1946); MEDLINE In-Process & Other Non-Indexed Citations
via OVID; Embase via OVID (from1980); and Cumulative Index
to Nursing and Allied Health Literature (CINAHL) via EBSCO
from 1960 to the present.
Unpublished studies
Conference Proceedings Citation Index (CPCI) via Web of Sci-
ence™ (from 1990); Zetoc (from 1993); and SCI Science Cita-
tion Index Expanded via Web of Science™ (from 1900), using
the “Proceedings and Meetings Abstracts” Limit function.
Trials registers
The US National Institutes of Health Ongoing Trials Reg-
ister ClinicalTrials.gov (www.clinicaltrials.gov); NIHR Clinical
Research Network Portfolio Database (www.nihr.ac.uk/research-
and-impact/nihr-clinical-research-network-portfolio/); and the
World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies, regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits. Update searches will be time-
and resource-dependent.
Searching other resources
Due to time restrictions and the volume of evidence retrieved from
the electronic searches, we will not conduct any handsearching of
conference proceedings. By searching CENTRAL, we will retrieve
relevant records identified by regular handsearching by Cochrane
Skin. The handsearched conferences and journals are listed here:
www.skin.cochrane.org/resources-handsearchers.
We will include information about potentially relevant ongoing
studies in the ’Characteristics of ongoing studies’ tables. We will
screen any relevant systematic reviews identified by the searches for
their included primary studies, and we will include any that our
searches havemissed in the review. Wewill check the reference lists
of all included papers, and subject experts within the author team
will review the final list of included studies. We may use citation-
searching for key references when we consider it appropriate.
Data collection and analysis
Selection of studies
Due to the volume of records retrieved, at least one review author
(JDi or NC) has undertaken screening of the titles and abstracts,
with any queries discussed and resolved by consensus. A pilot ex-
ercise independently screening 539 references from MEDLINE
showed a good level of agreement (89% with a kappa of 0.77).
So far, we have selected 822 records for full-text review for the
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staging reviews. At least two review authors, including methodol-
ogists (JDi or NC) and clinical reviewers, using a study eligibility
screening proforma based on prespecified inclusion criteria, will
independently undertake subsequent assessment of potentially rel-
evant full-text articles for the staging reviews (Appendix 3).Where
differences in opinion exist, a third review author, drawing on the
clinical and methodological expertise in the team as appropriate to
the content of the query (JDe, CD, HW, and RM) will help with
resolution. We will compile a list of otherwise eligible studies for
which insufficient data were presented to allow for the construc-
tion of a 2 x 2 contingency table, andwewill contact study authors,
asking them to provide the relevant data. We will describe the
study selection process in an adapted PRISMA flowchart (Liberati
2009). At the full-text inclusion stage, we will tag studies accord-
ing to their target condition (melanoma or cSCC) and index test.
Data extraction and management
We will carry out data extraction using a predesigned and piloted
data extraction form in Excel, to ensure that we collect relevant
data. At least two review authors will independently extract details
of the study design, participants, index test(s) or test combinations
and criteria for index test positivity, reference standards, and data
required to populate a 2 x 2 diagnostic contingency table for each
index test. We will record where data are available at several index
test thresholds. A third review author, drawing on clinical and
methodological expertise in the team as appropriate to the content
of the query, will resolve discrepancies.
We will try to contact authors of included studies where informa-
tion is missing that we consider key to one or more of the assess-
ments of the quality of an included study, investigation of het-
erogeneity, or completion of a 2 x 2 diagnostic contingency table.
We will follow up studies published only as conference abstracts,
to identify whether a full paper has been published. Where possi-
ble, we will contact the authors of conference abstracts published
from 2015 to 2016 and ask whether full data are available. If we
can identify no full paper, we will mark conference abstracts as
’pending’ and revisit them. Experience of contacting authors for
information about missing data in DTA reviews is limited. Where
we seek missing data, we will therefore document the outcome of
contact with the authors.
Dealing with multiple publications and companion papers
In the event of multiple reports of a primary study, we will exam-
ine all available data to determine the potential for overlapping
populations and to identify a primary data source. Where we sus-
pect overlapping study populations and are unable to identify a
primary data source, we will contact study authors for clarification
in the first instance. If contact with authors is unsuccessful, we
will use the most complete and up-to-date data source available,
thus avoiding the risk of double-counting. We will examine the
impact of inconsistencies in reporting of 2 x 2 data that remain
unresolved in a sensitivity analysis.
Assessment of methodological quality
Wewill assess the applicability and risks of bias of included studies
using the QUADAS-2 checklist (Whiting 2011), which has been
tailored to the review topic (see Table 4).
Participant selection domain (1)
Selective recruitment of study participants can be a key influence
on test accuracy. In general terms, all participants eligible to un-
dergo a test should be included in a study, allowing for the in-
tended use of that test within the context of the study.
Inappropriate participant exclusions affecting the internal validity
of a study of staging might include the exclusion of those with
primary tumours at particular sites or exclusion of those with un-
successfully-mapped SLNs.
For SLNB studies, the applicability of a study’s results will be
affected by the participant spectrum according to the clinical stage
of disease (AJCC stage) and site of the primary tumour.
Imaging tests may be undertaken following diagnosis of the pri-
mary cSCC lesionor followingdisease recurrence, such that studies
may include mixed populations of participants. Given the poten-
tial for variation in test accuracy according to participant spectrum
and disease prevalence (Brenner 1997; Leeflang 2013; Mulherin
2002), the applicability of results will be affected by the propor-
tion of participants undergoing primary staging versus staging for
disease recurrence, as well as by the clinical stage of disease (AJCC
stage or clinical nodal status) and site of the primary tumour.
Index test domain (2)
Given the subjectivity of test interpretation, particularly for imag-
ing tests, the interpretation of the index test blinded to the re-
sult of the reference standard is a key means of reducing bias. For
prospective studies, the index tests will by nature be interpreted
before the result of the reference standard is known; however, ret-
rospective studies will be susceptible to information bias, either
if the person abstracting data from medical records is aware of
individual patients’ final diagnoses, or if any reinterpretation of
images is undertaken for the purposes of the study.
For imaging tests, studies reporting the accuracy of multiple diag-
nostic thresholds (different tumour characteristics or parameters)
for the same index test will also be subject to information bias un-
less each characteristic was interpreted by a different reader. This
would be an impractical and unlikely approach for most studies,
but we include a quality item in order to highlight any studies
where this occurs, to facilitate discussion.
In terms of applicability, despite the often subjective nature of
test interpretation, it is important that study authors outline the
particular characteristics that they considered to be indicative of
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the presence of disease, so that appropriate comparisons can be
made between test evaluations and the test can be replicated in
practice. For SLNB, a descriptionof the tracer threshold for a “hot”
versus a “cold” node will be required, as well as a description of the
histology interpretation, such as the Royal College of Pathologists
(RCP) requirements (Royal College of Pathologists 2014).
The experience of the observer will also impact on the applicabil-
ity of study results. Detailed information on the experience and
training of care providers is often lacking, such that a detailed
analysis of the impact of examiner experience may not be possible.
However to be considered ‘low concern’:
• surgical members of the specialist skin cancer
multidisciplinary team (SSMDT) should meet guideline
recommendations, i.e. carrying out at least 15 inguinal or
axillary lymph node dissections a year (NHS England 2014)
• imaging tests should be interpreted by consultant
radiologists
Reference standard domain (3)
In an ideal study, consecutively-recruited participants should all
undergo the same reference standard. In reality, both partial and
differential verification biases are likely.
Partial verification bias will occur where histology (e.g. complete
lymph node dissection) is the only reference standard used, and
only those participants with a certain degree of suspicion of ma-
lignancy based on the result of the index test undergo verification,
the others either being excluded from the study or being defined
as disease-negative without further assessment or follow-up.
Differential verification bias will be present where other reference
standards are used in addition to histological verification. Differ-
ential verification is inevitable in these reviews, because of the in-
vasive nature of obtaining tissue samples for histological confirma-
tion of presence/absence of malignancy. This is particularly true
where complete lymph node dissection is the reference standard
for detection of nodal metastases, as this will not be undertaken in
those who have a negative SLNB. With imaging tests, histological
confirmation would be impossible following a negative imaging
result; however, those with borderline or indeterminate results are
also unlikely to have subsequent histology. Any indeterminate re-
sults will be reviewed at the MDT and a decision made whether
to repeat the imaging in three months, for example, or to image
with a different modality to clarify. With borderline imaging, the
finding is usually too small to be called ametastasis, making biopsy
very unlikely for practical reasons.
Absence of disease in test-negative participants will therefore be
confirmed by another concurrent imaging test (which will have its
own false-negative (FN) and false-positive (FP) rate), or preferably
by clinical or radiological follow-up. Ideally, a follow-up-based
reference standard should be long enough to allow all present
but ‘hidden’ cases of disease to become detectable (Naaktgeboren
2013); however, differentiating disease that was originally present
but missed from newly-emergent disease is problematic.
For the SLNB review, we will require studies to report the emer-
gence of clinically-detectable ormacroscopic nodal disease in SLN-
negative participants in order to be included; therefore, we will
judge all SLNB studies to have used an adequate reference stan-
dard. For the imaging reviews, wewill define an adequate reference
standard for imaging test-negative participants as clinical or radi-
ological follow-up to detect any metastatic disease. We will rate
studies that use a concurrently-applied imaging test to determine
final diagnosis of index test-negative participants at high risk of
bias.
A further challenge is the potential for incorporation bias, i.e.
where the result of the index test is used to help determine the
reference standard diagnosis. For both SLNB and imaging tests,
only those with positive test results will undergo any procedure
to allow histological confirmation (whether core biopsy, SLNB or
complete lymph node dissection). In each case, the histopathol-
ogist will probably be aware that the index test was positive, and
this knowledge will inform the pathology procedure.
There is also considerable potential for the clinicians or radiologists
concerned with the clinical and/or radiological follow-up of study
participants to identify any subsequent emergence of nodal or
distant disease to be aware of the original index test result and to
use that to inform diagnostic decisions at the time of follow-up.
Reference standard blinding is therefore extremely unlikely and
its enforcement would significantly limit the generalisability of
the study results. We will therefore assess the presence of blinded
reference test interpretation (as it is a standard QUADAS-2 item),
but will not include it in our overall assessment of bias.
Flow and timing domain (4)
A period of one month has been defined as an appropriate interval
(low risk of bias) between application of the index test and a his-
tological reference standard (complete lymph node dissection or
biopsy of possible distant metastases). Where the reference stan-
dard is follow-up-based, we have applied no restrictions on follow-
up timing.
Comparative domain
In the event that we identify comparative imaging test studies, we
will add a comparative domain to the QUADAS-2 checklist (Ap-
pendix 4). Questions reflect the possibility of selection bias (into
the study and allocation to index test or testing strategies) and as-
sessment of blinding of interpretation of each individual index test
for within-person comparisons. In addition, for within-person test
comparisons we have specified a maximum of one month between
application of individual index tests, as intervals greater than this
may be accompanied by changes in tumour characteristics. This
is an arbitrary threshold, and in the event that a large proportion
of included studies exceed this time period, we will undertake a
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sensitivity analysis to investigate the impact of this quality item
on estimates of accuracy.
We will initially pilot the amended checklist tool on a small num-
ber of included full-text articles. Ttwo review authors will inde-
pendently rate each study on the four quality domains (patient
selection, index test(s), reference standard, flow and timing). They
will resolve any disagreements by consensus or by recourse to a
third review author.
We will narratively summarise the results of quality assessment for
all included studies at domain level, highlighting those domains
that pose the greatest potential for risk of bias and concern about
applicability for the body of evidence.Wewill supplement the nar-
rative summary with summary graphics and tables as appropriate,
to assist with the presentation of the results of quality assessment
across included studies for important participant subgroups and
by index test.
Statistical analysis and data synthesis
We anticipate a paucity of studies in this area, such that a only
narrative review will be appropriate. However, if we find enough
studies, we will apply the following methodology:
For the SLNBreviews, our primary analysis will focus on the detec-
tion of metastases in the investigated nodal basin. For the imaging
test reviews, we will conduct separate analyses, firstly according to
whether study participants are recruited on primary presentation
of cSCC or with a disease recurrence, and secondly according to
our primary and secondary objectives, i.e. detection of any metas-
tasis (which must include both nodal and distant recurrence) and
detection of nodal metastasis alone or detection of any distant
metastasis, as defined under Target condition being diagnosed).
SLNB is not used for staging of recurrence in skin cancer.
Studies may report test accuracy by lesion or by patient. Our unit
of analysis for the primary analyses will be the patient, as study
participants may have multiple metastatic sites at any one time,
such that a ’by lesion’ analysis may overestimate test accuracy. We
will include data from studies that reported ’by lesion’-level data in
secondary analyses, such that by-lesion and by-patient data from
different studies would be combined together, using by-patient
data in preference where both are reported within a study. The
estimation of the accuracy metrics to be used in our reviews is
detailed in Appendix 4.
For the SLNB review, both index test and reference standard pos-
itivity are defined histologically. In the absence of an additional
suitable reference standard for SLNB test positivity, it will not be
possible to estimate false positive cases, and specificity will always
be 100%. We will therefore perform meta-analysis only of sen-
sitivities by using a univariate random-effects logistic regression
model. We will also estimate the pooled negative predictive value
in a secondary analysis (the positive predictive value will not be
possible to calculate due to false positives not being estimable).
The definitions for each cell of the 2 x 2 contingency tables for
the SLNB review are as follows:
• TP = SLN-positive (i.e. all participants with a positive SLN,
regardless of any subsequent recurrence)
• FP = not possible to estimate
• FN = SLN-negative participants who experience clinical
emergence of disease in the same nodal basin, in the absence of
disseminated disease
• TN = SLN-negative participants who do not experience
clinical emergence of disease in same nodal basin
For the imaging test reviews, we will estimate sensitivity and speci-
ficity in the usual way. We will initially explore the data by plot-
ting estimates of sensitivity and specificity on coupled forest plots
and in receiver operating characteristic (ROC) space for each in-
dex test under consideration. We will use hierarchical models to
perform meta-analyses (Macaskill 2013). Where commonly-used
thresholds are reported,wewill produce summary operating points
(summary sensitivities and specificities) with 95% confidence and
prediction regions, using the method of Reitsma 2005. Where
different thresholds are used, we will fit a summary curve using
a hierarchical summary ROC (HSROC) model (Rutter 2001).
When few studies are available for meta-analysis, we will simplify
hierarchical models as appropriate, depending on whether the fo-
cus of inference is a summary point or summary curve (Takwoingi
2015). We anticipate that in many instances results frommultiple
thresholds within a single study may be reported. Where we need
to select multiple thresholds for the review, we may use data from
the same participants more than once in each analysis. For the
analysis of summary curves, however, we will select standard or
most commonly-used thresholds from each study. Failing that, we
will select one threshold at random from each study.
For the imaging tests review, if sufficient data are available we will
perform both direct and indirect comparisons (the latter being
required because we anticipate that comparative studies may be
scarce (Takwoingi 2013)). To formally compare index tests, we
will add a covariate for test type to the relevant hierarchical model.
We will use likelihood ratio tests to assess the statistical signifi-
cance of differences in test accuracy (sensitivity and specificity) for
analyses of summary points and shape and accuracy for analyses
of summary curves, by comparing models without the covariate
terms with models containing the covariate terms.
We will conduct analyses using Review Manager 5 (RevMan
2014), the NLMIXED procedure in SAS, and the meqrlogit com-
mand in STATA 14.
Investigations of heterogeneity
We will initially examine heterogeneity between studies by visu-
ally inspecting the forest plots of sensitivity and specificity and
summary ROC plots. Where a sufficient number of studies have
assessed the same index test and the characteristics of interest (see
Secondary objectives) were adequately reported to enable analyses,
we will perform meta-regression by adding the potential source
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of heterogeneity as a covariate to a hierarchical model. We will
require at least five studies in each subgroup; we will only report
heterogeneity analyses with fewer than five studies in each group
when we can be convinced that models have achieved adequate
convergence and that the distribution of studies across groups is
adequate to provide valid estimates. Where factors to be investi-
gated (e.g. AJCC stage of disease) could vary between participants
within a study, we will rely on the inclusion criteria set out by the
study authors (such as restriction to stage II, III, or IVmelanoma),
or use the results of any subgroup analyses within a study to exam-
ine the effect of that covariate. We will assess each of the factors
listed under the secondary objectives where possible.
Sensitivity analyses
If enough studies (at least five) assess the same index test, we will
perform sensitivity analyses, restricted according to:
• those with direct test comparisons (where the period of
application between the index tests was within one month);
• where concerns around applicability for participant
selection are low;
• where there was low risk of bias for the index test; and
• where there was low risk of bias for the reference standard
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we will not perform
tests to detect publication bias.
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Adjuvant therapy or treatment A treatment given after the main treatment for cancer to reduce the risk of recurrence
Adnexal (in relation to the skin) Structures in the skin including hair follicles and sebaceous glands
Biopsy Removal of a sample of tissue from the body to assist in diagnosis or inform the choice
of treatment of a disease
Computed tomography (CT) Imaging technique inwhich the person lies on a table within a x-ray gantry. The images
are acquired using a spiral (helical) path and banks of detectors, allowing presentation
of the internal organs and blood vessels in different projections including 3-D views
Curettage Surgical procedure to remove tissue or delineate borders of lesions via scraping
Cutaneous T cell lymphoma A type of non-Hodgkin lymphoma of the skin caused by uncontrolled growth of white
blood cells
Dermal papilla Small projections of the dermis into the overlying epidermis giving an undulating
pattern and visible as “fingerprints” in hands and feet
Electrodessication The use of high-frequency electric currents to cut, destroy or cauterise tissue. It is
performed with the use of a fine needle-shaped instrument
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies
as disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies as having
the disease
Follicular bulge The portion of the hair follicle that contains the stem cells that give rise to skin cells. It
contains the cells needed for wound repair, hair growth and development and tumour
development
Histopathology The study of tissue, usually obtained by biopsy or excision, for example under a
microscope
Incidence The number of new cases of a disease in a given time period
interfollicular epidermis The part of the skin that lies in between the hair follicles
Local recurrence Regrowth of a tumour in the area from which it was originally removed
Locoregional recurrence Regrowth of a tumour in the area from which it was originally removed or in the
regional lymph nodes (usually nearest to the original tumour site)
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Table 1. Glossary of terms (Continued)
Lymph node dissection Surgical removal or one or more lymph nodes in the absence of proven involvement
with melanoma
Lymph node dissection (lymphadenectomy) A surgical operation to remove one or more groups of lymph nodes
Lymphoscintigraphy An imaging technique used to identify the lymph drainage basin, determine the num-
ber of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the
sentinel node in an unexpected location, and mark the sentinel node over the skin
for biopsy. It requires the injection of a radio-isotope into the skin around the biopsy
scar and a scan some hours later to determine to which lymph nodes the tracer has
travelled
Magnetic resonance imaging (MRI) A type of scan which uses a magnetic field and radio waves to produce images of
sections of the body
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual
studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Metastases so small that they can only be seen under a microscope
Morbidity Detrimental effects on health
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age
group, disease, treatment or other classification, usually expressed as deaths per 100,
1000, 10,000 or 100,000 people
Multidisciplinary team (MDT) A team with members from different healthcare professions and specialties (e.g. urol-
ogy, oncology, pathology, radiology, and nursing). Cancer care in the NHS uses this
system to ensure that all relevant health professionals are engaged to discuss the best
possible care for that patient
Oncology The study of cancers. This term also refers to the medical specialty of cancer care, with
particular reference to the use of radiotherapy or drugs to treat cancer. The medical
specialty is often split into Clinical Oncology (doctors who use radiotherapy and drug
treatment) and Medical Oncology (doctors who use drug treatment)
Palpation Feeling with the fingers or hands as part of a clinical examination of the body
Perineural involvement Spread or invasion of cancer to the nerves
Positron emission tomography (PET) A nuclear medicine imaging technique whereby a radioactive glucose (usually 18FDG)
is administered intravenously before a scan is conducted to create an image using
colours to show where the FDG (or other radioactive tracer) has been taken up in the
body
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Table 1. Glossary of terms (Continued)
Prevalence The proportion of a population found to have a condition
Prognostic factors / indicators Specific characteristics of a cancer or the person who has it which might affect the
patient’s prognosis
Radiotherapy The use of radiation, usually high energy x-rays, to control the growth of cancer cells
Recurrence New cancer cells are detected following treatment. This can occur either at the site of
the original tumour or at other sites in the body
Relapse Where cancer starts to grow again after treatment
Sensitivity In this context, the proportion of individuals with a disease who have that disease
correctly identified by the study test
Sentinel lymph node biopsy A radioactive tracer and blue dye are injected into the skin surrounding the primary
lesion and the ’sentinel’ lymph nodes to which the tracer drains are located by imaging
(usually lymphoscintigraphy), and then removed and examined for nodal metastatic
spread that cannot be detected clinically or on imaging
Specificity The proportion of individuals without a disease who have the absence of disease
correctly identified by the study test (i.e. the study test is negative)
Staging Clinical description of the size and spread of a patient’s tumour, fitting into interna-
tionally agreed categories
Stem cells Biological cells that can self-renew and can differentiate into specialised cells; stem
cells contribute to maintaining and protecting the skin and allowing hair regrowth
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting one specific area
Ultrasound A type of scan in which high-frequency sound waves are used to outline a part of the
body
Some of the definitions above have been obtained from the NICE Guideline for the management of melanoma (NICE 2015).
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Table 2. AJCC TNM staging for cutaneous cutaneous squamous cell carcinoma
Classification Criteriaa
T
Tis Carcinoma in situ
T1 Tumor ≤ 2 cm at largest horizontal width and < 2 high-risk features
T2 Tumor > 2 cm at largest horizontal width or any size with ≥ 2 high-risk features
T3 Infiltration of facial and cranial bones
T4 Infiltration of skeletal bone or skull base
N
N0 No regional lymph node metastases
N1 Solitary, ipsilateral lymph node metastasis, maximum diameter ≤ 3 cm
N2a Solitary, ipsilateral lymph node metastasis, maximum diameter > 3 cm to max. 6 cm
N2b Multiple, ipsilateral lymph node metastases, all with a maximum diameter ≤ 6 cm
N2c Multiple, bilateral or contralateral lymph node metastases, all with a maximum diameter ≤ 6 cm
N3 Lymph node metastasis, diameter > 6 cm
M
M0 No distant metastases
M1 Distant metastases
Table based on that reported in Edge 2010
AJCC: American Joint Committee on Cancer;
aHigh-risk features include depth/invasion (> 2 mm thickness, Clark level ≥ IV, or perineural invasion), anatomical location (primary
site on the ear or the non-hair-bearing lip), and differentiation (poorly differentiated or undifferentiated).
Table 3. Alternative Tumour Staging System for cutaneous squamous cell carcinoma
Classification Criteria a
Tis Carcinoma in situ
T1 0 risk factors
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Table 3. Alternative Tumour Staging System for cutaneous squamous cell carcinoma (Continued)
T2a 1 risk factor
T2b 2 to 3 risk factors
T3 4 risk factors or bone invasion
Alternative system proposed by Jambusaria-Pahlajani 2013 and adapted in Schmitt 2014.
aRisk factors include tumour diameter of ≥ 2 cm, poorly-differentiated histological characteristics, perineural invasion, and tumour
invasion beyond the subcutaneous fat (excluding bone invasion, which automatically upgrades the tumour to alternative stage T3).
Table 4. QUADAS interpretation
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g. needs ex-
amples of inappropriate exclusions in this context - for both
melanoma and for cutaneous squamous cell carcinoma (cSCC)
staging?
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.g.
indeterminate results or where disagreement between evaluators
was observed
Unclear - if not clearly reported
4) For between-person comparative (BPC) studies only (i.e. allo-
cating different tests to different study participants such as ran-
domised controlled trials (RCTs)):
• a) were the same participant selection criteria used for those
allocated to each test?
Yes - if same selection criteria were used for each index test
No - if different selection criteria were used for each index test
Unclear - if selection criteria per test were not described
N/A - if only one index test was evaluated or all participants re-
ceived all tests
• b) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
Yes - if adequate randomisation procedures are described
No - if inadequate randomisation procedures are described
Unclear - if the method of allocation to groups is not described
(a description of ‘random’ or ‘randomised’ is insufficient)
N/A - if only one index test was evaluated or all participants re-
23Tests to assist in the staging of cutaneous squamous cell carcinoma: a generic protocol (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. QUADAS interpretation (Continued)
ceived all tests
• c) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
Yes - if appropriate methods of allocation concealment are de-
scribed
No - if appropriate methods of allocation concealment are not
described
Unclear - if themethod of allocation concealment is not described
(sufficient detail to allow a definite judgement is required)
N/A - if only one index test was evaluated
Could the selection of participants have introduced bias?
v FOR NON-COMPARATIVE (NC) STUDIES
If answers to all of questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk Unclear
v FOR BETWEEN-PERSON COMPARATIVE STUDIES
If answers to all of questions 1) and 2) and 3) and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) or 4) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) or 4) was ‘Unclear’: Risk Unclear
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
For sentinel lymph node biopsy and imaging tests:
1)Does the study report results for participants unselected by stage
of disease or site of primary lesion, i.e. the study does not focus
solely on those with a particular stage of disease such as AJCC I
or melanoma <=1 mm in thickness?
Yes - if an unrestricted group of participants have been included
No - if a selected group of study participants have been included,
e.g. those with clinical stage I disease or only those with thin
melanoma
Unclear - if insufficient details are provided to determine the
spectrum of included participants
2) Did the study report data on a per-patient rather than per-
lesion basis?
Yes - if a per-patient analysis was reported
No - if a per-lesion analysis only was reported
Unclear - if it is not possible to assess whether data are presented
on a per-patient or per-lesion basis
For imaging tests only:
3) Does the study focus primarily on participants undergoing pri-
mary staging or those undergoing staging for disease recurrence?
Yes - if at least 80% of study participants are undergoing primary
staging following diagnosis of a primary cutaneous melanoma or
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Table 4. QUADAS interpretation (Continued)
staging of recurrence
No - if less than 80% of study participants are undergoing primary
staging following diagnosis of a cutaneous melanoma or staging
of recurrence
Unclear - if insufficient details are provided to determine the
proportion of patients undergoing primary staging versus those
undergoing staging of recurrence
Is there concern that the included participants do not match the review question?
If the answer to question 1) or 2) (and 3)) was ‘Yes’: Concern is Low
If the answer to question 1) or 2) (and 3)) was ‘No’: Concern is High
If the answer to question 1) or 2) (and 3)) was ‘Unclear’: Concern is Unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result, or for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
For imaging tests only:
3) For studies reporting the accuracy ofmultiple diagnostic thresh-
olds (tumour characteristic or parameter) for the same index test,
was each threshold interpreted without knowledge of the results
of the others?
Yes - if thresholds were selected prospectively and each was inter-
preted by a different reader, or if study implements a retrospective
(or no) cutoff
No - if study uses prospective threshold and report states reported
by same reader
Unclear - if no mention of number of readers for each threshold
or if pre-specification of threshold not reported
N/A - multiple diagnostic thresholds not reported for the same
index test
4) For within-person comparisons (WPC) of index tests or testing
strategies (i.e. > 1 index test applied per participant), was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
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Table 4. QUADAS interpretation (Continued)
N/A - if only one index test was evaluated
Could the conduct or interpretation of the index test have
introduced bias?
v FOR NC and BPC STUDIES item 3) / 4) to be added
If answers to questions 1) and 2) was ‘Yes’: Risk is Low
If answers to either questions 1) or 2) was ‘No’: Risk is High
If answers to either questions 1) or 2) was ‘Unclear’: Risk is Unclear
v FOR WPC STUDIES
If answers to all questions 1), 2) for any index test and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) for any index test or 3) was
‘No’:
Risk is High
If answers to any one of questions 1) or 2) for any index test or 3) was
‘Unclear’:
Risk is Unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
This item applies equally to studies using objective and more
subjective approaches to test interpretation. For SLNB studies,
this requires description of the tracer threshold for identification
of the SLN and the histological assessment
Yes - if the criteria for diagnosis of the target disorder were reported
in sufficient detail to allow replication
No - if the criteria for diagnosis of the target disorder were not
reported in sufficient detail to allow replication
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided
2) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by an experienced examiner as
defined in the review protocol
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported
in sufficient detail to judge or if examiners described as ’Expert’
with no further detail given
Is there concern that the index test, its conduct, or interpretation differ from the review question?
If answers to questions 1) and 2) was ‘Yes’: Concern is Low
If answers to questions 1) or 2) was ‘No’: Concern is High
If answers to questions 1) or 2) was ‘Unclear’: Concern is Unclear
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Table 4. QUADAS interpretation (Continued)
REFERENCE STANDARD (3) - RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
a) DISEASE POSITIVE - One or more of:
- Histological confirmation of metastases following lymph node
dissection (or SLNB or core biopsy for imaging studies)
- Clinical/radiological follow up to identify clinically detectable
disease in a mapped nodal basin (SLNB studies)
- Clinical/radiological follow up to identify any metastases (imag-
ing studies) subsequently confirmed on histology
Yes - if all disease positive participants underwent one of the listed
reference standards
No - if a final diagnosis for any disease positive participant was
reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any disease positive participant
b) DISEASE NEGATIVE - One or more of:
- Histological confirmation of absence of disease in a mapped
nodal basin following lymph node dissection (or following SLNB
for imaging studies)
- Clinical/radiological follow up of test negative participants
Yes - if at least 90% of disease negative participants underwent
one of the listed reference standards
No - if more than 10% of benign diagnoses were reached by
concurrent imaging test
Unclear - if the method of final diagnosis was not reported for
any participant with benign or disease negative diagnosis
2) Were the histology-based reference standard results interpreted
without knowledge of the results of the index test?
Yes - if the histopathologist was described as blinded to the index
test result
No - if the histopathologist was described as having knowledge of
the index test result
Unclear - if blinded histology interpretation was not clearly re-
ported
3) Were the reference standard results based on patient follow-up
interpreted without knowledge of the results of the index test?
Yes - if the clinician or radiologist was described as blinded to the
index test result
No - if the clinician or radiologist was described as having knowl-
edge of the index test result
Unclear - if blinded interpretation was not clearly reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Does the study use the same definition of disease positive as the
primary review question or is it possible to fully disaggregate data
such that data matching the review question can be extracted?
Yes - same definition of disease positive used, or patients can be
disaggregated and regrouped according to review definition
No - some patients cannot be disaggregated
For SLNB review - disease positive includes participants with any
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Table 4. QUADAS interpretation (Continued)
nodal recurrence (not restricted to clinical recurrence in same
nodal basin)
For imaging reviews - participants with nodal versus distant re-
currences cannot be disaggregated
Unclear - definition of disease positive not clearly reported
For studies of imaging tests:
2)The result of another imaging test (without patient follow-up to
determine later emergence of disease) was not used as a reference
standard
Yes - if imaging-based diagnosis was not used as a reference stan-
dard for any participant
No - if imaging-based diagnosis was used as a reference standard
for any participant
Unclear - if not clearly reported
3) Item on observer experience could be included?
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
If answers to all questions 1), 2) and 3) was ‘Yes’: Concern is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Concern is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Concern is Unclear
***For teledermatology studies only:
If answers to questions 1) and 3) was ‘Yes’: Concern is Low
If answers to questions 1) or 3) was ‘No’: Concern is High
If answers to questions 1) or 3) was ‘Unclear’: Concern is Unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
• a) For index test positive participants, was the interval
between index test and histological reference standard <= 1
month?
Yes - if study reports <= 1 month between index and histological
reference standard
No - if study reports > 1 month between index and histological
reference standard
Unclear - if study does not report interval between index and
histological reference standard
• b) If reference standard is clinical or imaging-based follow
up of index test negative participants, was there less than 6
months between application of index test(s) and first follow-up
visit?
Yes - if study reports a follow-up visit within 6 months of appli-
cation of the index test
No - if study reports the first follow-up visit beyond 6 months of
the index test
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Table 4. QUADAS interpretation (Continued)
Unclear - if study does not report timing of follow-up visits
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than one reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear - if not clearly reported
4) For WITHIN-PERSON COMPARISONS (WPC) of index
tests:
Was the interval between application of index tests <= 1 month?
Could the participant flow have introduced bias?
Yes - if study reports <= 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report interval between index tests
v FOR NON-COMPARATIVE and BPC STUDIES
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
v FOR WITHIN-PERSON COMPARATIVE STUDIES (WPC)
If answers to all questions 1), 2), 3), and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1), 2), 3), or 4) was ‘No’: Risk is High
If answers to any one of questions 1), 2), 3), or 4) was ‘Unclear’: Risk is Unclear
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
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LIST OF REVIEWS Estimated number of studies
Diagnosis of melanoma
1 Visual inspection 50
2 Dermoscopy 88
3 Teledermatology 15
4 Mobile phone applications 2
5a Computer-aided diagnosis - dermoscopy-based techniques 37
5b Computer-aided diagnosis - spectroscopy-based techniques This review will be amalgamated into 5a
6 Reflectance confocal microscopy 19
7 High frequency ultrasound 5
8 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
9 Visual inspection +/- Dermoscopy 22
10a Computer-aided diagnosis - dermoscopy-based techniques 3
10b Computer-aided diagnosis - spectroscopy-based techniques This review will be amalgamated into 10a
11 Optical coherence tomography 5
12 Reflectance confocal microscopy 9
13 Exfoliative cytology 9
14 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Staging of melanoma
15 Ultrasound 25 - 30
16 CT 5 - 10
17 PET or PET-CT 20 - 25
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(Continued)
18 MRI 5
19 Sentinel lymph node biopsy +/- high frequency ultrasound 70
20 Overview: Comparing the accuracy of tests for which sufficient
evidence is identified either alone or in combination
Number not estimable
Staging of cSCC
21 Imaging tests review 10 - 15
22 Sentinel lymph node biopsy +/- high frequency ultrasound 15 - 20
Appendix 2. MEDLINE (OVID) search strategy
Database: Ovid MEDLINE(R) <1946 to August 2016 (as run on 28 August 2016) FINAL
Amended Search Strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 exp Neoplasms, basal cell/
5 basalioma$1.ti,ab.
6 ((basal cell or skin) adj2 (cancer$ or carcinoma$1 or mass or masses or tumour$ or tumor$ or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
7 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
8 (melanom$ or nonmelanoma$ or non-melanoma$ or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
9 nmsc.ti,ab.
10 rodent ulcer$.ti,ab.
11 (squamous cell adj2 (cancer$ or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
12 (BCC or CSCC or NMSC).ti,ab.
13 keratinocy$.ti,ab.
14 Keratinocytes/
15 or/1-14 (253324)
16 dermoscop$.ti,ab.
17 dermatoscop$.ti,ab.
18 photomicrograph$.ti,ab.
19 exp epiluminescence microscopy/
20 Microscopy, Confocal/
21 (epiluminescence adj2 microscop$).ti,ab.
22 (confocal adj2 microscop$).ti,ab.
23 Tomography, Optical Coherence/
24 Dielectric Spectroscopy/
25 Cytodiagnosis/
26 (incident light adj2 microscop$).ti,ab.
27 (surface adj2 microscop$).ti,ab.
28 (visual adj (inspect$ or examin$)).ti,ab.
29 ((clinical or physical) adj examin$).ti,ab.
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30 3 point.ti,ab.
31 three point.ti,ab.
32 pattern analys$.ti,ab.
33 ABCD$.ti,ab.
34 menzies.ti,ab.
35 7 point.ti,ab.
36 seven point.ti,ab.
37 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
38 artificial intelligence.ti,ab.
39 AI.ti,ab.
40 computer assisted.ti,ab.
41 computer aided.ti,ab.
42 neural network$.ti,ab
43 exp diagnosis, computer-assisted/
44 MoleMax.ti,ab.
45 image process$.ti,ab.
46 automatic classif$.ti,ab.
47 image analysis.ti,ab.
48 SIAscop$.ti,ab.
49 Aura.ti,ab.
50 (optical adj2 scan$).ti,ab.
51 MelaFind.ti,ab.
52 SIMSYS.ti,ab.
53 MoleMate.ti,ab.
54 SolarScan.ti,ab.
55 VivaScope.ti,ab.
56 (high adj3 ultraso$).ti,ab.
57 (canine adj2 detect$).ti,ab.
58 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
59 smartphone$.ti,ab.
60 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
61 Mole Detective.ti,ab.
62 Spot Check.ti,ab.
63 (mole$1 adj2 map$).ti,ab.
64 (total adj2 body).ti,ab.
65 exfoliative cytolog$.ti,ab.
66 digital analys$.ti,ab.
67 (imag$ adj3 software).ti,ab.
68 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
69 (optical coherence adj (technolog$ or tomog$)).ti,ab.
70 OCT.ti,ab.
71 (computer adj2 diagnos$).ti,ab.
72 exp sentinel lymph node biopsy/)
73 (sentinel adj2 node).ti,ab.
74 nevisense.mp. or HFUS.ti,ab.
75 electrical impedance spectroscopy.ti,ab.
76 history taking.ti,ab
77 patient history.ti,ab.
78 (naked eye adj (exam$ or assess$)).ti,ab.
79 (skin adj exam$).ti,ab.
80 physical examination/
81 ugly duckling.mp. or UD.ti,ab.
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82 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
83 ABCDE.mp. or VOC.ti,ab.
84 clinical accuracy.ti,ab.
85 Family Practice/ or Physicians, Family/ or clinical competence/
86 (confocal adj2 microscop$).ti,ab.
87 diagnostic algorithm$1.ti,ab.
88 checklist$.ti,ab.
89 virtual imag$.ti,ab.
90 volatile organic compound$1.ti,ab.
91 dog$1.ti,ab.
92 gene expression analy$.ti,ab.
93 reflex transmission imag$.ti,ab
94 thermal imaging.ti,ab.
95 elastography.ti,ab.
96 or/16-95 (849678)
97 (CT or PET).ti,ab.
98 PET-CT.ti,ab.
99 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
100 exp Deoxyglucose/
101 deoxy-glucose.ti,ab.
102 deoxyglucose.ti,ab.
103 CATSCAN.ti,ab. 104 exp Tomography, Emission-Computed/
105 exp Tomography, X-ray computed/
106 positron emission tomograph$.ti,ab.
107 exp magnetic resonance imaging/
108 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
109 exp echography/
110 Doppler echography.ti,ab.
111 sonograph$.ti,ab.
112 ultraso$.ti,ab.
113 doppler.ti,ab)
114 magnetic resonance imag$.ti,ab.
115 or/97-114 (1337432)
116 (stage$ or staging or metasta$ or recurr$ or advanced or sensitivity or specificity or false negative$ or thickness$).ti,ab.
117 “Sensitivity and Specificity”/
118 exp cancer staging/
119 or/116-118 (2164365)
120 115 and 119
121 96 or 120
122 15 and 121 (18542)
Appendix 3. Full-text eligibility criteria
The study: Response (enter X if any of the exclusion criteria are met)
• is not a primary study
• is a conference abstract only
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(Continued)
• is a systematic review
• does not allow accuracy to be estimated separately for either
melanoma or cSCC participants
• (for SLNB) does not report outcomes for both SLN+ and
SLN- patients
• (for SLNB) does not report recurrence in the investigated
nodal basin
• (for imaging) does not report detection of nodal or distant
recurrence (or any recurrence)
• (for melanoma only) includes < 5 diseased or < 5
nondiseased participants
• (for cSCC) no sample size limit
• evaluates an ineligible index test (eligible tests are SLNB,
US, CT, PET or PET-CT, MRI)
• is a surveillance (follow-up) study using repeat or serial
imaging
• does not use an eligible reference standard
• does not assess test accuracy (i.e. 2 x 2 cannot be derived)
cSCC: cutaneous squamous cell carcinoma.
SLNB: sentinel lymph node biopsy.
US: ultrasound.
CT: computerised tomography.
PET: positron emission tomography.
PET-CT: positron emission tomography-computed tomography.
MRI: magnetic resonance imaging.
Appendix 4. Calculation of diagnostic accuracy statistics
i) Contingency table (2 x 2 table)
Reference standard
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+ve
Diseased
-ve
Nondiseased
Index test result
+ ve
True positives a b False positives Total test positive
- ve False negatives c d True negatives Total test negative
Total diseased Total nondiseased
ii) Diagnostic accuracy indices
Sensitivity Proportion of diseased who have positive test
results
True positives / Total diseased
a / (a + c)
Specificity Proportion of nondiseased who have negative
test results
True negatives / Total nondiseased
d / (b + d)
Positive predictive value (PPV) Proportion with positive test result who actually
have the disease
True positives / Total test positive
a / (a + b)
Negative predictive value (NPV) Proportion with negative test result who really
do not have the disease
True negatives / Total test negative
d / (c + d)
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